Amalgamated Bank Has $9.67 Million Stake in IDEXX Laboratories, Inc. $IDXX

Amalgamated Bank boosted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.1% during the second quarter, Holdings Channel reports. The institutional investor owned 18,026 shares of the company’s stock after acquiring an additional 711 shares during the quarter. Amalgamated Bank’s holdings in IDEXX Laboratories were worth $9,668,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Mutual of America Capital Management LLC boosted its holdings in IDEXX Laboratories by 79.6% during the first quarter. Mutual of America Capital Management LLC now owns 19,430 shares of the company’s stock valued at $8,160,000 after purchasing an additional 8,609 shares in the last quarter. Plato Investment Management Ltd lifted its position in shares of IDEXX Laboratories by 37.1% during the 1st quarter. Plato Investment Management Ltd now owns 3,087 shares of the company’s stock worth $1,310,000 after buying an additional 835 shares during the period. Genesis Wealth Advisors LLC acquired a new stake in IDEXX Laboratories in the 2nd quarter valued at $215,000. ORG Wealth Partners LLC bought a new stake in IDEXX Laboratories in the second quarter valued at $273,000. Finally, Symmetry Partners LLC bought a new stake in IDEXX Laboratories in the second quarter valued at $266,000. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

IDXX stock opened at $628.54 on Friday. The company has a 50 day moving average price of $638.21 and a 200 day moving average price of $565.90. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $688.12. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79. The stock has a market capitalization of $50.28 billion, a PE ratio of 52.33, a price-to-earnings-growth ratio of 4.06 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Monday, August 4th. The company reported $3.63 EPS for the quarter, beating analysts’ consensus estimates of $3.28 by $0.35. The firm had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.06 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The business’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same period last year, the company earned $2.44 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Insiders Place Their Bets

In other news, Director M Anne Szostak sold 2,187 shares of the firm’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $647.33, for a total value of $1,415,710.71. Following the transaction, the director owned 262 shares of the company’s stock, valued at approximately $169,600.46. This trade represents a 89.30% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Nimrata Hunt sold 7,143 shares of the business’s stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $630.43, for a total transaction of $4,503,161.49. Following the sale, the executive vice president directly owned 18,007 shares of the company’s stock, valued at approximately $11,352,153.01. This trade represents a 28.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 54,057 shares of company stock valued at $34,293,468 over the last 90 days. Corporate insiders own 0.98% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on IDXX shares. Weiss Ratings reissued a “buy (b-)” rating on shares of IDEXX Laboratories in a report on Wednesday, October 8th. Morgan Stanley lifted their price target on shares of IDEXX Laboratories from $722.00 to $765.00 and gave the company an “overweight” rating in a report on Friday, August 15th. Piper Sandler reaffirmed a “neutral” rating and set a $700.00 price objective (up from $510.00) on shares of IDEXX Laboratories in a research note on Monday, August 11th. Wall Street Zen lowered shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Sunday, September 28th. Finally, BTIG Research lifted their target price on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the company a “buy” rating in a research note on Tuesday, August 5th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $656.50.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.